Ensoma Launches With Takeda Partnership On Myeloablation-Free Gene Therapy
Executive Summary
The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.
You may also be interested in...
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Pipeline Packed As Cash Pours Into Cell And Gene Therapy Space
Cell, gene and RNA therapies are starting to transform the healthcare landscape and a report from the American Society of Gene + Cell Therapy and Informa Pharma Intelligence maps the progress the sector made in the first quarter of 2021.